In life sciences the marketing question is upstream of any channel decision: what may be said about this product, to this audience, at this stage. A device before clearance, a drug in trials, a research reagent and an approved therapy are four different regimes, and an agency that starts with a channel plan rather than a claims discussion has begun in the wrong place. The review workflow is not overhead here; it is the product.
The claim comes before the campaign
Everything published has to be consistent with what the product is approved, cleared or lawfully marketed for, and the boundary differs by product type and stage. Prescription drug advertising is governed in detail, including requirements around fair balance and the presentation of risk information, at 21 CFR 202.1. An agency working here needs to be comfortable being told no by regulatory affairs, repeatedly, and to design work that survives that.
Medical, legal and regulatory review is the schedule
In practice the review cycle sets the pace of everything. Agencies that are new to the sector plan as if approval were a formality and then miss every date. Ask how the agency structures work for review: modular claims with references attached, assets built so a single change does not restart the cycle, and realistic lead times. A team that has done this will describe the process without being prompted.
Know which audience you are allowed to address
Healthcare professionals, patients, payers and investigators can be addressed differently, and in some markets direct-to-consumer communication is not permitted at all. Gating, targeting and even site architecture follow from that. An agency should ask which audiences are in scope in the first conversation, and should raise the multi-market question if you sell outside the United States, because what is lawful here is not lawful everywhere.
Congresses and field teams are part of the same program
In this sector a large share of the audience is reached at scientific meetings and through medical science liaisons and field sales, not through paid media. Digital work that ignores those channels duplicates effort and sometimes contradicts them. Ask how the agency coordinates with congress activity and with what the field team is permitted to say, because misalignment there is visible to the customer immediately.
Patient stories carry both advertising and privacy obligations
A patient testimonial in this sector is governed both by what may be claimed about outcomes and by privacy rules, and requires written authorization rather than verbal agreement. The FTC's endorsement guides require honest presentation of results that are not typical and disclosure of material connections. Agencies that treat patient content as ordinary marketing material create exposure the manufacturer carries.
Questions people ask about life science digital marketing
Do we need a specialist life science agency?
Usually yes, not for creative reasons but because the review workflow, the claims discipline and the audience rules are learned rather than intuited. A generalist can produce excellent work that cannot be approved, which costs more than a specialist would have. Test for the competence directly by asking how they structure assets for review.
Can we run search ads for a prescription product?
It depends on the product, the market and the audience, and the rules governing prescription drug advertising are detailed, including how risk information must be presented. This is a question for regulatory affairs first and an agency second. Any agency that answers it confidently without asking about the product and market has told you something useful about itself.
How long does approval take?
It varies enormously by organization, from days for a minor change with a standing precedent to many weeks for new claims. The controllable part is how work is constructed: modular, referenced and built so one comment does not invalidate the whole asset. Agencies that plan for this hit their dates; agencies that treat review as a rubber stamp do not.
What about unbranded disease awareness content?
It is a common and legitimate route, and it has its own boundaries, particularly around not implying a specific product. Keep the governance as tight as for branded work, because the reputational and regulatory risk of an unbranded campaign that reads as a product claim is the same, and the review discipline is what keeps the two apart.